Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
Open Access
- 14 May 2025
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-20
Abstract
Background and aims: Diabetic cardiomyopathy (DbCM) is recognised as a key mediator and determinant of heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). Improved understanding of mechanisms underlying transition from early-stage DbCM to HFpEF will inform innovative evidence-based treatment approaches, which are urgently required to alleviate increasing disease burden. This study aimed to determine whether inhibition of neprilysin activity by Sacubitril/Valsartan in both experimental and clinical DbCM attenuates adverse remodelling through promotion of cardioprotective signalling. Methods and results: Sacubitril/Valsartan effectively reduced plasma neprilysin activity in both diabetic patients with pre-clinical HFpEF from the PARABLE trial (baseline (Val n = 25; Sac/Val n = 35) and 3 months after treatment (Val n = 21/25; Sac/Val n = 33/35)) and DbCM (high-fat diet and streptozotocin) mice. Plasma neprilysin activity at baseline was correlated with worsening cardiac performance at 18 months indicated by left atrial stiffness index in patients (n = 44/60), whilst diastolic dysfunction and pathological remodelling in DbCM mice were improved by Sacubitril/Valsartan, but not Valsartan. snRNA-sequencing showed that progressive experimental DbCM is characterised by chronic low-grade inflammation, reflected by increased infiltration of pro-inflammatory monocytes (Ccr2+ Ly6chi) and reduction in MHC-II macrophages, which was prevented by Sacubitril/Valsartan. Informatics analysis implicated IRF7 as a central mediator of Sacubitril/Valsartan-induced immunomodulation in DbCM, whilst treatment of M2-like pro-repair macrophages with the neprilysin inhibitor, LBQ657 and Valsartan suppressed glucose-induced IRF7 expression and paracrine activation of cardiac fibroblast differentiation in vitro. Conclusion: Immune cells are significantly involved in DbCM progression, impacting myocardial homeostasis and HF progression. Neprilysin inhibition by Sacubitril/Valsartan improved adverse cardiac remodelling in experimental DbCM through direct regulation of inflammation, highlighting immunomodulation as a novel mechanism underlying established its cardioprotective actions. GraphicalKeywords
Funding Information
- Queen’s University Belfast
- The Heartbeat Trust
- British Heart Foundation (PG/20/10424)
This publication has 46 references indexed in Scilit:
- Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2023
- Effects of Sacubitril/Valsartan on Neprilysin Targets and The Metabolism of Natriuretic Peptides in Chronic Heart Failure: A Mechanistic Clinical StudyEuropean Journal of Heart Failure, 2018
- Revealing the Critical Regulators of Cell Identity in the Mouse Cell AtlasCell Reports, 2018
- Augmentation of Glucagon-Like Peptide-1 Receptor Signalling by Neprilysin Inhibition: Potential Implications for Patients with Heart FailureEuropean Journal of Heart Failure, 2018
- Single-Cell Transcriptional Profiling Reveals Cellular Diversity and Intercommunication in the Mouse HeartCell Reports, 2018
- Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart diseaseDiabetologia, 2017
- Attenuation of Monocyte Chemotaxis—A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic PeptideJournal of Cardiovascular Translational Research, 2013
- Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatmentHeart Failure Reviews, 2011
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972